Sign inJoin waitlistJoin the waitlist

Faye Johnson

Professor · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2000–2002
Internal Medicine
Baylor College of Medicine
1997–2000
McGovern Medical School at The University of Texas Health Science Center at Houston
1992–1996

Research

Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial
JAMA Oncology · 2019 · 410 citations
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung…
Clinical Cancer Research · 2005 · First of 4 authors · Corresponding · 274 citations
Regulation of SRC family kinases in human cancers
Journal of Signal Transduction · 2011 · 191 citations

Jeffrey Myers
28 papers
BG
Bonnie Glisson
24 papers
John Heymach
18 papers
Clifton Fuller
16 papers · 3 as a fellow
Adam Garden
15 papers
David Rosenthal
15 papers
Renata Ferrarotto
14 papers
Stephen Lai
14 papers
Heath Skinner
13 papers · 1 as a resident
Katherine Hutcheson
13 papers
Lauren Byers
12 papers · 1 as a fellow
Steven Frank
12 papers

Grants

Targeting Head and Neck Cancer Cells and the Adverse Tumor Microenvironment with a Novel Small-Molecule STAT3 Inhibitor
National Cancer Institute · R01
PI · $1.7M · University of Tx Md Anderson Can Ctr
2022–2027
Harnessing Aurora Kinase Inhibition‐Induced Cell Death to Enhance Immunotherapy in HPV‐Driven Cancers
National Cancer Institute · R01
Contact PI · $1.8M · University of Tx Md Anderson Can Ctr
2020–2025
Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC)
National Cancer Institute · R01
Contact PI · $3.2M · University of Tx Md Anderson Can Ctr
2019–2024
Targeting c-Src in Head and Neck Cancer
National Cancer Institute · R01
Contact PI · $1.2M · University of Tx Md Anderson Can Ctr
2010–2015

Clinical trials

Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)
Principal investigator · Withdrawn · Phase 1, Phase 2
M.D. Anderson Cancer Center
2025
Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer
Principal investigator · Completed · Phase 1, Phase 2
M.D. Anderson Cancer Center
2020–2025
Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations
Principal investigator · Terminated · Phase 2
M.D. Anderson Cancer Center
2019–2020
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
Principal investigator · Completed · Phase 1, Phase 2
M.D. Anderson Cancer Center
2009–2014